BACKGROUND: Single-session stereotactic radiosurgery (SRS) treatment of vestibular schwannomas results in excellent tumor control. It is not known whether functional outcomes can be improved by fractionating the treatment over multiple sessions. OBJECTIVE: To examine tumor control and complication rates after multisession SRS. METHODS: Three hundred eighty-three patients treated with SRS from 1999 to 2007 at Stanford University Medical Center were retrospectively reviewed. Ninety percent were treated with 18 Gy in 3 sessions, targeting a median tumor volume of 1.1 cm 3 (range, 0.02-19.8 cm 3 ).
V estibular schwannoma (VS; also known as acoustic neuroma) is a benign Schwann cell-derived tumor arising from the vestibular portion of the eighth cranial nerve. The overall incidence is 1 per 100 000, with approximately 3000 cases diagnosed per year in the United States. Likely because of the wide use of imaging, there is a rise in both the incidence and earlier detection of VS.
1 Common presenting symptoms include hearing loss, tinnitus, vertigo, and balance and gait disturbance. Tumor progression can lead to brainstem compression, cranial neuropathies, and hydrocephalus. Treatment options are observation, microsurgical resection, conventionally fractionated radiotherapy, and stereotactic radiosurgery (SRS).
Reports of excellent tumor control rates after single-session SRS [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] have established SRS as a good treatment option. Treatment-related cranial nerve complications after single-session SRS can include hearing loss, facial nerve palsy, and trigeminal dysfunction. In an effort to improve functional outcomes, the dose for singlefraction SRS has been reduced from previous doses of 16 to 20 Gy to the currently accepted dose of 12 to 13 Gy. 3, [16] [17] [18] According to radiobiological principles, administration of radiation over multiple fractions may decrease the risk of normal tissue toxicity compared with single-session treatments. 19 Our practice has been to reduce the dose radiobiologically through the use of multiple treatment sessions to lessen the risk of cranial nerve complications. Our preliminary experience showed comparable rates of tumor control with a suggestion of improved toxicity profile compared with singlesession SRS. 20 Here, we present our tumor control and complication results of multisession SRS treatment of VS. To the best of our knowledge, this is the largest published series investigating this technique.
METHODS Patient Characteristics
Patient data were obtained from Stanford University institutional review board-approved review of a prospectively maintained database of patients treated with SRS at Stanford University Medical Center. From 1999 to 2007, 474 patients with VSs were treated with SRS. Ninety-one patients had either no (n = 62) or , 1 year of imaging (n = 29) follow-up information. Three hundred eighty-three patients with . 1 year of follow-up data were analyzed. Facial nerve function, hearing, and tumor volume/mass effect were classified with the House-Brackman, 21 Gardner-Robertson, 22 and Koos scales, 23 respectively.
Patient demographic information is summarized in Table 1 . One hundred eighty-one female patients (47%) and 202 male patients (53%) were treated at a median age of 54 years (range, 11-91 years). The tumor was located on the left in 188 patients (49%) and right in 195 patients (51%). Forty-one patients (11%) had received prior microsurgical resection. Fifteen patients (4%) had a diagnosis of neurofibromatosis type 2 (NF2). Before SRS, 324 patients (85%) presented with symptoms related to VS, most commonly hearing loss of some degree (92%). Additional symptoms at presentation included tinnitus (49%), ataxia/ disequilibrium (46%), diminished sensation of the ipsilateral trigeminal nerve dermatome(s) (7%), trigeminal neuralgia (2%), facial weakness (9%), 21 and hemifacial spasm (2%). ). Ninety percent of the patients (n = 368) were treated with 18 Gy in 3 sessions. Twenty-two patients (9.6%) were NF2 patients (n = 15) or were treated before 2000 (n = 7) when the treatment dose was decreased. In an attempt to decrease complication risks from SRS further, our total dose was decreased from 21 to 18 Gy in 3 sessions in early 2000. This was analogous to the dose de-escalation trend observed with single-session SRS, demonstrating decreased cranial nerve injury without compromising tumor control. 18, 24 Those who had no useful hearing before SRS were treated with a single dose of 12 to 15 Gy (n = 13). The prescription isodose line ranged from 65% to 95% (median, 80%). Conformity index ranged from 1.03 to 3.39 (median, 1.41).
Treatment Characteristics

Radiosurgical Technique
The CyberKnife Robotic Radiosurgical System (Accuray, Sunnyvale, California) was used to deliver the radiosurgical treatments. A highresolution thin-slice (1.25 mm) computed tomogram (CT) was obtained with a GE Light Speed 8i or 16i Scanner (Milwaukee, Wisconsin) after administration of 125 mL Omnipaque intravenous contrast (Iohexol, 350 mg I/mL; GE Health Care, Princeton, New Jersey). The stereotactic magnetic resonance imaging (MRI) scan was fused to the CT scan in all patients except those patients with contraindication for MRI scan or those few patients who refused MRI because of claustrophobia. Figure 1 shows a sample CT fusion with MRI SRS plan of a patient with a VS. The neurosurgeon, radiation oncologist, and radiation physicist performed tumor delineation, dose selection, and planning. Treatment plans were generated with the CyberKnife nonisocentric iterative inverse treatment planning software. Quality of treatment plans was assessed by evaluating target coverage, dose heterogeneity, and conformality. The conformity index (prescribed isodose volume/tumor volume encompassed by the prescription isodose line) and the modified conformity index ([prescribed isodose volume 3 tumor volume encompassed by the prescription isodose line]/tumor volume 2 ) were calculated. [25] [26] [27] [28] Digitally reconstructed radiographs were synthesized computationally to allow real-time patient tracking throughout radiosurgery. Informed consent for treatment was obtained from all patients. Patients received 4 mg dexamethasone immediately after each treatment. For multisession treatments, the typical interfraction time interval was 24 hours.
Follow-up
Patients were followed up with MRI scan, audiogram, and clinic visits (including detailed neurological examination) every 6 months for the first 2 years. After the fourth post-SRS year, follow-up visits were conducted every 2 years.
Statistics
All statistical analyses were performed with Stat View, version 5.0.1 (SAS Institute Inc, Cary, North Carolina). The tumor control rate, defined as the absence of the need for additional surgical or radiosurgical intervention, was calculated with the Kaplan-Meier product-limit method. 29 Tumor/local control rate is defined as needing no additional treatment (ie, microsurgical resection, repeat SRS). Time to local failure was calculated from the date of SRS to the date of intervention; otherwise, patients were censored at the time of their last follow-up MRI scan. Preservation of serviceable hearing is defined as maintenance of Gardner-Robertson grade 1 to 2 hearing after SRS.
Log-rank test and univariate Cox proportional hazard regression were used to assess categorical and continuous variables, respectively. Univariate tests were not adjusted for multiple comparisons. Differences between the groups were assessed with the Fisher exact test and a 2-tailed t test for categorical and continuous data sets, respectively.
RESULTS
Tumor Control
Of the 383 patients, 10 tumors exhibited progressive growth requiring additional treatment (microsurgical resection [n = 9] and repeat SRS [n = 1]; Table 3 ). With a median follow-up duration of 3.6 years (range, 1-10 years), the 3-and 5-year Kaplan-Meier resection/repeat SRS-free tumor control rates were 99% and 96%, respectively ( Figure 2 ). The median time from SRS to date of additional treatment was 3.4 years (range, 1.8-5.7 years). Complications from post-SRS microsurgical resection included new or worsening facial weakness (n = 3) and worsening trigeminal neuropathy (n = 2). All of these patients had no useful hearing before post-SRS microsurgical resection.
Multisession SRS was used in 370 patients; the 3-and 5-year Kaplan-Meier tumor control rates for patients treated with multisession SRS were 99% and 96%, respectively. On univariate analysis, tumor volume, as a continuous variable, was associated with a trend toward treatment failure (P = .12); the 3-and 5-year Kaplan-Meier tumor control rates for the largest quartile tumors (. 3.4 cm 3 ) were 99% and 89%, respectively, compared with 99% and 98% for the rest (P = .07). The NF2-associated tumors had worse tumor control compared with sporadic tumors. The 3-and 5-year Kaplan-Meier tumor control rates for sporadic vs NF-2-associated tumors were 99% and 96% compared with 93% and 84%, respectively (P = .03). Factors not associated with tumor control included location (right vs left; P = .9), prior surgery (P = .34), and conformity index (P = .8).
Hearing Preservation
Of the 383 patients, 96 (25%) had nonserviceable hearing (ie, Gardner-Robertson grade 3, 4, or 5) before SRS. Pretreatment Smaller tumor volume was associated with a higher hearing preservation rate after SRS (P = .001, with tumor volume as a continuous variable). Tumors , 3 cm 3 had a serviceable hearing preservation rate of 80% compared with 59% for tumors $ 3 cm 3 (P = .009). There was a trend toward hearing preservation for younger age (P = .06) and intracanalicular tumors (P = .19); crude hearing preservation rates for Koos stage I compared with Koos stage II, III, and IV tumors were 83% vs 73%, respectively (P = .19).
Nonauditory Complications
There were 19 total cases of nonauditory complications. There were 8 trigeminal nerve complications (2%): 6 patients developed facial paresthesias, 2 of whose symptoms resolved completely. Two patients reported transient trigeminal neuralgia-like pain; both remain symptom free. Additionally, the degree of facial numbness in each of these patients was mild and not bothersome. There was no case (0%) of post-SRS facial weakness. Hemifacial spasm occurred in 8 patients (2%). The symptoms of 7 of 8 patients were self-limited and disappeared over time. Four patients (1%) required ventriculoperitoneal shunt placement; however, none had fourth ventricular obstruction as the cause of hydrocephalus. Larger tumor volume was associated with risk of nonauditory complications (P = .009, with tumor volume as a continuous variable), with largest quartile tumors (3.4 cm 3 ) having a complication rate of 9.6% compared with 3.5% for the rest (P = .03). Similarly, the rate of nonauditory complications for Koos stage IV tumors was 9.3% compared with 3.8% for Koos stage I, II, and III tumors (P = .05).
DISCUSSION
Since Dr Lars Leksell first reported the use of Gamma Knife for VS, 30 SRS has evolved considerably. High rates of tumor control have been reported with the Gamma Knifebased 2-4,7-11,13,15,31,32 and linear accelerator-based SRS, 6, 33, 34 conventionally fractionated stereotactic radiotherapy, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] and proton beam irradiation. [45] [46] [47] Given the excellent rates of tumor control, more attention is being paid to functional outcomes such as hearing, trigeminal nerve, and facial nerve preservation. The radiobiological rationale behind fractionation is to minimize radiation-induced normal tissue complications. However, conventionally fractionated radiotherapy schedules, requiring 5 to 6 weeks of daily treatments, are inconvenient for some and impossible for those living distant from a radiation facility. What is not known is whether fractionating over 3 sessions would confer benefit over single-session treatments. Based on the radiobiological principals of fractionation and encouraged by our previously published experience of treating VSs using 21 Gy in 3 sessions resulting in a 77% hearing preservation rate, 48 our practice has been to treat VSs with multisession SRS. 20 We retrospectively reviewed the outcomes of these patients to determine the rates of tumor control, hearing preservation, and nonauditory complications.
First, multisession SRS results in excellent tumor control. The tumor control rates reported here (3-and 5-year Kaplan-Meier local control rates of 99% and 96%, respectively) are comparable to those of other large (. 100 cases) series of single-session SRS for VS (90%-98%; summarized in Table 4 ) and series of conventionally fractionated radiotherapy ( Table 5 ). The majority of patients in this series were treated with 18 Gy over 3 days with a frameless system. Analogous to the dose de-escalation trend observed with single-session SRS, our total dose was decreased starting in early 2000 from 21 to 18 Gy in 3 sessions; the rate of tumor control with the lower dose of 18 Gy is equivalent to our earlier experience of using 21 Gy in 3 sessions. 48 In our series, tumor volumes . 3.4 cm 3 and a diagnosis of NF2 were associated with decreased tumor control. These findings are in agreement with prior studies showing worse tumor control with larger tumors 2,4,13,49 or diagnosis of NF2. [50] [51] [52] In contrast, Pollock et al 53 and Arthurs et al 54 did not find a significant association between tumor control and diagnosis of NF2 or tumor size, respectively. Nine patients in the present series underwent delayed microsurgical resection after SRS failure. Of these, there were 3 cases of new or worsening facial weakness and 2 cases of worsening trigeminal neuropathy. Similar rates of complications were reported after delayed postmicrosurgical resection by other investigators. [55] [56] [57] [58] [59] Next, we examined hearing preservation, an important functional outcome for patients with VS. The detrimental effect of radiation on auditory organs is well documented, 42, [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] but the exact mechanism remains not well understood. Although the higher rate of hearing preservation reported in the more recent series 3, 13, 16, 24, 32, 35, 37, [39] [40] [41] [42] 44, 50, [72] [73] [74] [75] [76] [77] is encouraging, there is still a great need for improvement.
Two key treatment parameters in SRS are dose and fractionation. First, improved hearing preservation can be achieved with a lower radiation dose. A recent analysis of 45 published articles representing 4234 patients treated with Gamma Knife SRS showed an overall hearing preservation rate of 51%; the authors found dose to be a statistically significant factor associated with hearing preservation (hearing preservation rate of 60.5% at # 13 Gy vs 50.4% at . 13 Gy: P = .001). 63 The effect of the second treatment parameter, fractionation, on hearing preservation is less clear. Although the 70% to 100% hearing preservation rate reported with conventionally fractionated radiotherapy (Table 5) 35-44 is promising, no prospective, randomized study has evaluated the effects of fractionation (with either conventional fractionation schedules or 2-to 5-session SRS) on hearing preservation. A retrospective study by Andrews et al 35 reported a 2.5-fold increase in hearing preservation in the conventionally fractionated radiotherapy group compared with SRS; however, studies from 2 other centers failed to confirm this finding. 42, 78 The serviceable hearing preservation rate of 76% in our series is superior to that of the compiled single-session SRS analysis reported by Yang et al 63 (overall hearing preservation rate of 51%; 60.5% hearing preservation with dose # 13 Gy) and is in line with some single-institution series results (68%-77%). 4, 9, 11, 13 A shortcoming of the present series is that we have chosen to report hearing outcomes using the GardnerRobertson scale. This was done to allow comparison of our results with previously published results. However, the Gardner-Robertson scale provides a rather crude estimate of hearing and may overestimate functional hearing outcomes in some cases. Another shortcoming of our series is the number of patients for whom we do not have audiogram results. Thus, on the basis of currently available data, we cannot conclude that there is a hearing preservation outcome difference between single-session and multisession SRS. To this end, to properly examine the effects of fractionation on hearing preservation, a multi-institutionally generated, prospective collection of raw audiometric data is needed to further our understanding of hearing outcomes after SRS.
Favorable prognostic factors for hearing preservation in our series include younger age (trend) and smaller tumor volume. Additionally, in agreement with previous reports, 32, 75, 77, 79 Koos stage I tumors (ie, intracanalicular tumors) had a trend toward improved hearing preservation compared with those with higher Koos classification.
Nonauditory complications such as facial nerve palsy and trigeminal dysfunction can be quite disabling. As with hearing preservation, reduction of the prescription dose has resulted in a decreased risk of cranial nerve V and VII injury. 3, 80, 81 Rates of new-onset permanent and transient facial weakness of 0% to 5% and 1% to 10%, respectively, have been reported after 4.3 a n, number of patients evaluated for serviceable hearing preservation; N, number of patients evaluated for local control; NR, not reported. Only the latest published data from each institution are shown.
MULTISESSION SRS FOR VESTIBULAR SCHWANNOMAS
single-session SRS with 12 to 13 Gy. 2, 3, [5] [6] [7] [9] [10] [11] 13, 15, 16, 31, 74, 82 Trigeminal dysfunction is another well-recognized complication of SRS, with rates ranging from 0.7 to 5%. [3] [4] [5] 10, 11, 13, 15, 74 Although progress has been made, means to further reduce the risk of nonvestibular nerve complications are desired.
Previously published studies have produced conflicting results regarding the effect of fractionation. In a nonrandomized, retrospective study, 5-fraction SRS resulted in higher trigeminal nerve preservation compared with single-session SRS (98% vs 92%, respectively; P = .05). 78 In contrast, nonrandomized, retrospective comparison of SRS and conventionally fractionated RT resulted in no difference in trigeminal nerve outcomes. 35, 42 Tumor control and complication results of published series with single-session SRS, conventionally fractionated radiotherapy, and multisession SRS are summarized in Tables 4, 5 , and 6, respectively. Our results of 0% facial nerve weakness and 2% trigeminal dysfunction (half of which was transient) are promising. However, the retrospective nature of our and others' series and the range of complication rates in published reports make direct comparison difficult.
With recent advances in imaging and planning algorithms and lessons learned from previously treated case series, SRS for VS has yielded higher rates of hearing preservation along with less toxicity while maintaining similar tumor control rates [2] [3] [4] 6, 7, 10, 11, 13, 15, 16, 20, 32, 53, 54 compared with the earliest published reports of this technique. However, functional outcomes, particularly preservation of hearing, remain an area where further research may be beneficial. To this end, collaborative efforts to conduct multi-institutional, prospective studies are needed.
CONCLUSION
Multisession SRS with 18 Gy in 3 sessions results in excellent tumor control. The hearing preservation and nonauditory complication rates presented here are promising and comparable to those in other published series. Although hearing preservation rates are improved compared with earlier, higher-dose regimens, research is needed to further optimize the functional outcomes in our patients. Going forward, multi-institutional, prospective studies are desired to better evaluate SRS treatment outcomes. HANSASUTA ET AL
